Brincidofovir: Completed Phase III enrollment

Chimerix completed enrollment of 450 CMV-seropositive hematopoietic stem cell transplant (HSCT) recipients in the double-blind, placebo-controlled, international Phase III SUPPRESS trial evaluating 10...